Epidemiology of Healthcare-Associated Pneumonia (HCAP)

ABSTRACT

Healthcare-associated pneumonia (HCAP) represents a distinct syndrome, separate from both community-acquired pneumonia (CAP) and nosocomial pneumonia. Although patients with HCAP present from the community, the epidemiology and bacteriology of HCAP belie the community label. As such, highly resistant pathogens such as methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa are commonly seen in HCAP. Although the true prevalence of HCAP is unclear the proportion of pneumonias admitted to the hospital due to HCAP relative to CAP appears to be increasing. The attendant mortality of HCAP is higher than that reported in CAP and approximates that seen in hospital-acquired pneumonia (HAP). More precise instruments are needed to heighten clinicians' index of suspicion for treating probable resistant pathogens with appropriate empirical antibiotic choices.

KEYWORDS

Pneumonia - methicillin-resistant Staphylococcus aureus - health care–associated

REFERENCES

• 1 Hospital-Acquired Pneumonia Guideline Committee of the American Thoracic Society and Infectious Diseases Society of America . Guidelines for the management of adults with hospital-acquired pneumonia, ventilator-associated pneumonia, and healthcare-associated pneumonia.  Am J Respir Crit Care Med. 2005;  171 388-416
• 2 Kollef M H, Shorr A, Tabak Y P et al.. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia.  Chest. 2005;  128 3854-3862
• 3 Iregui M, Ward S, Sherman G et al.. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia.  Chest. 2002;  122 262-268
• 4 Alvarez-Lerma F. ICU-acquired Pneumonia Study Group . Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit.  Intensive Care Med. 1996;  22 387-394
• 5 Micek S T, Kollef K E, Reichley R M et al.. Healthcare-associated pneumonia and community-acquired pneumonia: a single-center experience.  Antimicrob Agents Chemother. 2007;  51 3568-3573
• 6 Carratala J, Mykietiuk A, Fernandez-Sabe N et al.. Healthcare-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy and clinical outcomes.  Arch Intern Med. 2007;  167 1393-1399
• 7 Shorr A F, Zilberberg M D, Micek S T et al.. Healthcare-associated pneumonia: a valuable concept at predicting resistant infections?.  Arch Intern Med. 2008;  , In press
• 8 Zilberberg M D, Shorr A F, Micek S T, Mody S H, Kollef M H. Antimicrobial therapy escalation and hospital mortality among patients with HCAP: A single center experience.  Chest. 2008 Jul 18;  , [Epub ahead of print]
• 9 Morin C A, Hadler J L. Population-based incidence and characteristics of community-onset Staphylococcus aureus infections with bacteremia in 4 metropolitan Connecticut areas, 1998.  J Infect Dis. 2001;  184 1029-1034
• 10 Friedman N D, Kaye K S, Stout J E et al.. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections.  Ann Intern Med. 2002;  137 791-797
• 11 Siegman-Igra Y, Fourer B, Orni-Wasserlauf R et al.. Reappraisal of community-acquired bacteremia: a proposal of a new classification for the spectrum of acquisition of bacteremia.  Clin Infect Dis. 2002;  34 1431-1439
• 12 McDonald J R, Friedman N D, Stout J E et al.. Risk factors for ineffective therapy in patients with bloodstream infections.  Arch Intern Med. 2005;  165 308-313
• 13 Naimi T S, LeDell K H, Como-Sabetti K et al.. Comparison of community- and health care–associated methicillin-resistant Staphylococcus aureus infection.  JAMA. 2003;  290 2976-2984
• 14 Tambyah P A, Habib A G, Ng T M et al.. Community-acquired methicillin-resistant Staphylococcus aureus infection in Singapore is usually “healthcare associated”.  Infect Control Hosp Epidemiol. 2003;  24 436-438
• 15 Shorr A F, Tabak Y P, Killian A D et al.. Healthcare-associated bloodstream infection: a distinct entity? Insights from a large US database.  Crit Care Med. 2006;  34 2588-2595
• 16 Shorr A F, Micek S T, Jackson W L et al.. Economic implications of an evidence-based sepsis protocol: can we improve outcomes and lower costs?.  Crit Care Med. 2007;  35 1257-1262
• 17 Shorr A F, Micek S T, Kollef M H. Inappropriate therapy for methicillin-resistant Staphylococcus aureus: resource utilization and cost implications.  Crit Care Med. 2008;  36 2335-2340
• 18 Moran G J, Krishnadasan A, Gorwitz R J et al.. Methicillin-resistant S. aureus infections among patients in the emergency department.  N Engl J Med. 2006;  355 666-674
• 19 Centers for Disease Control and Prevention . Severe Clostridium difficile–associated disease in populations previously at low risk—four states, 2005.  MMWR Morb Mortal Wkly Rep. 2005;  54 1201-1205
• 20 Centers for Disease Control and Prevention . Surveillance for community-associated Clostridium difficile—Connecticut, 2006.  MMWR Morb Mortal Wkly Rep. 2008;  57 340-343